Swissmedic publishes Information concerning an official Warning from Brazil regarding Falsified Medicinal Product
Recommendation

8 September 2026
Basel, Switzerland
Specifics in the Distribution of Medicinal Products
The Swissmedic has been informed by the Brazilian Health Regulatory Agency ANVISA that Brazil has suspended all imports of medicinal products from three Turkish wholesalers. The reason for this is the export of falsified units from Turkey to Brazil. One of the batches was also obtained from Turkey and sold to Brazil by a Swiss wholesaler.
In this regard, an information for Swiss companies was published. The Swissmedic points out that Swiss companies are also not permitted to supply medications obtained from the Turkish wholesalers to Brazil.
The names of the three wholesalers and further information can be found on the website of Swissmedic.
Related GMP News
18.06.2026GDPA Participated as an Observer in the EMA GMDP-IWG Interested Parties Meeting
18.06.2026Questions and Answers from the ECA Webinar "GDP Update 2026" - Part 4
18.06.2026GDP Non-Compliance Report: Missed CAPA Timelines lead to Refusal of GDP Certificate
17.06.2026European GDP Association Developments January through April 2026
12.05.2026How Are Service Providers Qualified in a GDP Environment?
12.05.2026Questions and Answers from the ECA Webinar "GDP Update 2026" - Part 3


